Journal of Cardiac Failure
Volume 14, Issue 5 , Pages 355-367, June 2008

Design of a Phase 1/2 Trial of Intracoronary Administration of AAV1/SERCA2a in Patients With Heart Failure

  • Roger J. Hajjar, MD

      Affiliations

    • Mount Sinai School of Medicine, New York, New York
    • Corresponding Author InformationReprint requests: Roger J. Hajjar, MD, Cardiovascular Research Center, Mount Sinai School of Medicine, One Gustave Levy Place, Box 1030, New York, NY 10029.
    • ,
  • Krisztina Zsebo, PhD

      Affiliations

    • Celladon Corporation, San Diego, California
    • ,
  • Lawrence Deckelbaum

      Affiliations

    • Johnson & Johnson Pharmaceutical Research & Development, LLC, Radnor, PA
    • ,
  • Craig Thompson, MD

      Affiliations

    • Division of Cardiology, Dartmouth College, Hanover, New Hampshire
    • ,
  • Jeff Rudy, MD

      Affiliations

    • Celladon Corporation, San Diego, California
    • ,
  • Alex Yaroshinsky, PhD

      Affiliations

    • Celladon Corporation, San Diego, California
    • ,
  • Hung Ly, MD

      Affiliations

    • Mount Sinai School of Medicine, New York, New York
    • ,
  • Yoshiaki Kawase, MD

      Affiliations

    • Mount Sinai School of Medicine, New York, New York
    • ,
  • Kim Wagner, MA

      Affiliations

    • Celladon Corporation, San Diego, California
    • ,
  • Kenneth Borow, MD

      Affiliations

    • Encorium Group, Inc., Wayne, Pennsylvania
    • ,
  • Brian Jaski, MD

      Affiliations

    • San Diego Cardiac Center/Sharp Hospital, San Diego, California
    • ,
  • Barry London, MD

      Affiliations

    • University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
    • ,
  • Barry Greenberg, MD

      Affiliations

    • University of California at San Diego Medical Center, San Diego, California
    • ,
  • Daniel F. Pauly, MD

      Affiliations

    • Shands Hospital, University of Florida, Gainesville, Florida
    • ,
  • Richard Patten, MD

      Affiliations

    • New England Medical Center, Tufts University, Boston, Massachusetts
    • ,
  • Randall Starling, MD

      Affiliations

    • Cleveland Clinic, Cleveland, Ohio
    • ,
  • Donna Mancini, MD

      Affiliations

    • Columbia University Hospital, New York, New York
    • ,
  • Mariell Jessup, MD

      Affiliations

    • Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania

Received 2 August 2007; received in revised form 5 February 2008; accepted 6 February 2008. published online 12 May 2008.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 Sponsored by Celladon Corporation which has supported the manufacture of AAV1/SERCA2a under the trade name MYDICAR. R.J.H. supported in part by grants from the National Institutes of Health: R01 HL078691, HL071763, HL080498, and HL083156, and is a scientific founder of Celladon Corporation (the company financing the trial). K.Z. is CEO of Celladon Corporation.

 L.D. employed by Johnson & Johnson, which has an equity investment in Celladon. K.B. employed by Encorium Inc., which is contracted by Celladon Corporation to conduct the clinical trial. J.R. is an employee and stock owner of Celladon Corporation.

PII: S1071-9164(08)00062-6

doi:10.1016/j.cardfail.2008.02.005

Journal of Cardiac Failure
Volume 14, Issue 5 , Pages 355-367, June 2008

Article Tools

* Image Usage & Resolution